# US 2019/0167624 A1 · Prevention and/or treatment of neurodegenerative disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167624 A1 - Document ID: US20190167624A1 - Status: Published application - Kind: A1 - Application number: 15/980,083 - Filed: 2018-05-15 - Published: 2019-06-06 - Earliest claimed: 2017-12-04 - Assignees: Howard Foundation Holdings Limited - Applicants: Howard Foundation Holdings Ltd - Inventors: Alan Norman HOWARD; John NOLAN; Riona MULCAHY - Web page: https://patentgrep.com/patent/US20190167624A1 ## CPC - A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) - A61K 31/047: having two or more hydroxy groups, e.g. sorbitol - A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203) - A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A method for the prevention and/or treatment of dementia in a human subject; the method comprising the step of administering an effective amount of a composition comprising at least one carotenoid selected from the group consisting of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid. ## Claims ### Claim 1 A method for the treatment of Alzheimer's disease in a human subject exhibiting one or more symptoms of Alzheimer's disease, the method comprising the step of administering an effective amount of a composition comprising each of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid, wherein the human subject to be treated has a mini mental state examination (MMSE) score of 25 or less. ### Claim 2 (canceled) ### Claim 3 (depends on 1) The method according to claim 1, wherein a single administered composition comprises each of lutein, zeaxanthin, meso-zeaxanthin and at least one omega-3 fatty acid. ### Claim 4 (depends on 1) The method according to claim 1, wherein the said at least one omega-3 fatty acid is docosahexaenoic acid. ### Claim 5 (depends on 1) The method according to claim 1, wherein the said at least one omega-3 fatty acid is provided in the composition as a fish oil. ### Claim 6 (depends on 1) The method according to claim 1, wherein the said at least one omega-3 fatty acid comprises at least two omega-3 fatty acids. ### Claim 7 (depends on 1) The method according to claim 1, wherein the omega-3 fatty acid-containing composition comprises docosahexaenoic acid and eicosapentaenoic acid. ### Claim 8 (depends on 1) The method according to claim 1, wherein the said at least one omega-3 fatty acid is provided as the free acid, as a salt or as a trigylceride. ### Claim 9 (depends on 8) The method according to claim 8, wherein the salt comprises a monocation. ### Claim 10 (depends on 8) The method according to claim 8, wherein the salt comprises a metal monocation. ### Claim 11 (canceled) ### Claim 12 (depends on 1) The method according to claim 1, wherein the composition/s is/are administered orally to the subject at least three times a week. ### Claim 13 (depends on 1) The method according to claim 1, wherein the composition/s is/are administered to the subject daily. ### Claim 14 (depends on 1) The method according to claim 1, wherein the composition/s is/are in unit dose form. ### Claim 15 (depends on 14) The method according to claim 14, wherein each unit dose of composition comprises about 10 mg meso-zeaxanthin, about 10 mg lutein, about 2 mg zeaxanthin, and fish oil containing said at least one omega-3 fatty acid. ### Claim 16 (depends on 14) The method according to claim 14, wherein each unit dose of composition comprises about 15 mg meso-zeaxanthin, about 5 mg lutein, about 1 mg zeaxanthin, and fish oil containing said at least one omega-3 fatty acid. ### Claim 17 (depends on 14) The method according to claim 14, wherein each unit dose of the composition comprises between about 20 mg and about 2 grams of docosahexaenoic acid. ### Claim 18 (depends on 14) The method according to claim 14, wherein each unit dose of composition comprises about 1 gram of fish oil containing said at least one omega-3 fatty acid. ### Claim 19 (depends on 1) The method according to claim 1, wherein the composition/s further comprise one or more of the following: acidity regulators; anticaking agents selected from the group consisting of sodium aluminosilicate, calcium or magnesium carbonate, calcium silicate, sodium and potassium ferricyanide; antioxidants selected from the group consisting of vitamin E, vitamin C, and polyphenols; colorings selected from the group consisting of artificial colorings FD&C Blue No. 1, Blue No. 2, Green No. 3, Red No. 40, Red No. 3, Yellow No. 5 and Yellow No. 6; and natural colorings selected from the group consisting of caramel, annatto, cochineal, betanin, turmeric, saffron, and paprika; color retention agents; emulsifiers; flavours; flavour enhancers; preservatives; stabilizers; sweeteners and thickeners. ### Claim 20 (depends on 1) The method according to claim 1, wherein the composition/s is/are in the form of a tablet or capsule. ### Claim 21 (depends on 1) The method according to claim 1, wherein the subject consumes the composition/s on a daily basis over a period of at least 12 months. ### Claim 22 (canceled) ### Claim 23 (canceled) ### Claim 24 (depends on 1) The method according to claim 1, comprising use of a composition consisting essentially of lutein, zeaxanthin, meso-zeaxanthin, at least one omega-3 polyunsaturated fatty acid or corresponding salt or triglyceride, and a diluent, carrier or excipient. ### Claim 25 (depends on 24) The method according to claim 24, wherein the omega-3 polyunsaturated fatty acid or corresponding salt or triglyceride is DHA or a salt or triglyceride of DHA. ### Claim 26 (depends on 1) The method according to claim 1, wherein the method comprises daily oral administration of a unit dose form composition comprising each of lutein; zeaxanthin; meso-zeaxanthin; and DHA and/or EPA, in preventing or retarding the progression of cognitive impairment in a subject already exhibiting one or more symptom of Alzheimer's disease prior to administration of the composition.